{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:24:30Z","timestamp":1760081070853,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s12032-017-1076-1","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T10:31:01Z","timestamp":1514543461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["First-line treatment with bendamustine and rituximab, in patients with intermediate-\/high-risk splenic marginal zone lymphomas"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-7690","authenticated-orcid":false,"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Bergamaschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Lambertenghi","family":"Deliliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"1076_CR1","doi-asserted-by":"crossref","unstructured":"Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica. 2010;95:1792\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20511668.","DOI":"10.3324\/haematol.2010.025437"},{"key":"1076_CR2","doi-asserted-by":"crossref","unstructured":"Boveri E, Arcaini L, Merli M, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol Off J Eur Soc Med Oncol. 2009;20:129\u201336. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18718888.","DOI":"10.1093\/annonc\/mdn563"},{"key":"1076_CR3","doi-asserted-by":"crossref","unstructured":"Spina V, Rossi D. Molecular pathogenesis of splenic and nodal marginal zone lymphoma. Best Pract Res Clin Haematol. 30:5\u201312. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28288716.","DOI":"10.1016\/j.beha.2016.09.004"},{"key":"1076_CR4","doi-asserted-by":"crossref","unstructured":"Castelli R, Wu MA, Arquati M, et al. High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency. Br J Haematol. 2016;172:902\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26728240.","DOI":"10.1111\/bjh.13908"},{"key":"1076_CR5","doi-asserted-by":"crossref","unstructured":"Arcaini L, Rossi D, Lucioni M, et al. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica. 2015;100:246\u201352. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25381127.","DOI":"10.3324\/haematol.2014.116855"},{"key":"1076_CR6","doi-asserted-by":"crossref","unstructured":"Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015;35:2222\u20137. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26104059.","DOI":"10.1111\/liv.12897"},{"key":"1076_CR7","unstructured":"Dasanu CA, Bockorny B, Grabska J, et al. Prevalence and pattern of autoimmune conditions in patients with marginal zone lymphoma: a single institution experience. Conn Med. 2015;79:197\u2013200. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26259295."},{"key":"1076_CR8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.autrev.2008.05.003","volume":"8","author":"M Cugno","year":"2008","unstructured":"Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev. 2008;8:156\u20139.","journal-title":"Autoimmun Rev"},{"key":"1076_CR9","doi-asserted-by":"crossref","unstructured":"Goldaniga M, Ferrario A, Cortelazzo S, et al. A multicenter retrospective clinical study of CD5\/CD10-negative chronic B cell leukemias. Am J Hematol. 2008;83:349\u201354. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18186522.","DOI":"10.1002\/ajh.21065"},{"key":"1076_CR10","doi-asserted-by":"crossref","unstructured":"Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101:2464\u201372. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12446449.","DOI":"10.1182\/blood-2002-07-2216"},{"key":"1076_CR11","doi-asserted-by":"crossref","unstructured":"Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br. J. Haematol. 2003;120:759\u201364. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12614206.","DOI":"10.1046\/j.1365-2141.2003.04165.x"},{"key":"1076_CR12","doi-asserted-by":"crossref","unstructured":"Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16493005.","DOI":"10.1182\/blood-2005-11-4659"},{"key":"1076_CR13","doi-asserted-by":"crossref","unstructured":"Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57\u201366. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26655425.","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"1076_CR14","doi-asserted-by":"crossref","unstructured":"Castelli R, Gidaro A, Deliliers GL. Bendamustine and Rituximab as first line treatment, in intermediate, high risk splenic marginal zone lymphomas of elderly patients. Mediterr J Hematol Infect Dis. 2016;8:e2016030. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27413523.","DOI":"10.4084\/mjhid.2016.030"},{"key":"1076_CR15","doi-asserted-by":"crossref","unstructured":"Arcaini L, Bruno R. Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol. 2010;5:74\u201381. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20156155.","DOI":"10.2174\/157488410791110751"},{"key":"1076_CR16","doi-asserted-by":"crossref","unstructured":"Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268\u201376. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11688461.","DOI":"10.1097\/00000478-200110000-00007"},{"key":"1076_CR17","doi-asserted-by":"crossref","unstructured":"Cervetti G, Ghio F, Cecconi N, et al. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases. J Chemother. 2017;29:126\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27454143.","DOI":"10.1080\/1120009X.2015.1114222"},{"key":"1076_CR18","doi-asserted-by":"crossref","unstructured":"Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127\u201331. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17514771.","DOI":"10.1002\/hon.820"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-1076-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1076-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-1076-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:16:14Z","timestamp":1570554974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-1076-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,29]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-1076-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2017,12,29]]},"article-number":"15"}}